Oncoceutics

Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The company’s leadership team represents a group of drug development executives with unparalleled success in the industry. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti-tumor activity in a number of different types of human cancer through a unique mechanism of action. The compelling preclinical efficacy and safety of ONC201 along with its favorable chemical properties offer a high potential for safe and meaningful therapeutic benefit to cancer patients in numerous clinical settings. Clinical lead indications for ONC201 are being evaluated in a series of clinical trials that are in various stages of initiation at leading cancer centers around the world. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti tumor activity in a number of different types of human cancer through a unique mechanism of action. ONC201 induces a striking cytotoxic response within tumors by engaging highly conserved apoptotic response mechanisms. ONC201s unique ability to engage these mechanisms selectively in tumors while sparing normal cells provides a wide spectrum of activity in early and late stage cancers that is accompanied by an attractive safety profile. The compelling preclinical efficacy and safety of ONC201 along with its favorable chemical properties offer a high potential for safe and meaningful therapeutic benefit to cancer patients in numerous clinical settings.